AC
INTS icon

Armistice Capital’s Intensity Therapeutics INTS Stock Holding History

Armistice Capital’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,902
Closed -$1.72M – 238
2025
Q1 		$1.72M Sell
34,902
-10,173
-23% -$566K 0.03% 153
2024
Q4 		$1.98M Buy
+45,075
New +$3.27M 0.03% 155

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Armistice Capital's INTS Position: Q2 2025 in Review

Armistice Capital sold out of Intensity Therapeutics (INTS) in Q2 2025, closing a stake of 34,902 shares — an estimated $1.72M sold.

Armistice Capital first reported a position in INTS in Q4 2024 and held it in 2 quarters. The position peaked at $1.98M in Q4 2024. 27 funds tracked by Wall St. Rank hold INTS as of Q2 2025.

  • Armistice Capital reported no remaining Intensity Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Armistice Capital sold 34,902 Intensity Therapeutics shares in Q2 2025, an estimated $1.72M.
  • Armistice Capital first reported a position in Intensity Therapeutics in Q4 2024 and held it in 2 quarters.
  • Armistice Capital's Intensity Therapeutics position peaked at $1.98M in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.